Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging

BACKGROUND: Accurate measurement of tumor burden in breast cancer disease is essential to improve the clinical management of patients. In this study, we evaluate whether the fluctuations in the fraction of PIK3CA mutant allele correlates with tumor response according to RECIST criteria and tumor mar...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Saenz, José Angel, Ayllón, Patricia, Laig, Marion, Acosta-Eyzaguirre, Daniel, García-Esquinas, Marta, Montes, Myriam, Sanz, Julián, Barquín, Miguel, Moreno, Fernando, Garcia-Barberan, Vanesa, Díaz-Rubio, Eduardo, Caldes, Trinidad, Romero, Atocha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362993/
https://www.ncbi.nlm.nih.gov/pubmed/28330468
http://dx.doi.org/10.1186/s12885-017-3185-9

Ejemplares similares

Ejemplares similares